Skip to content

The effects of whole-body vibration therapy on motor function, muscle tone, balance, walking endurance, and quality of life in children with cerebral palsy: a randomized controlled trial

The effects of whole-body vibration therapy on motor function, muscle tone, balance, walking endurance, and quality of life in children with cerebral palsy: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112839
Enrollment
Unknown
Registered
2025-11-20
Start date
2025-11-30
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral palsy

Interventions

Experimental group:Conventional treatment+whole-body vibration therapy
Control group:Conventional treatment

Sponsors

Lanzhou Disabled Care Employment Rehabilitation Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of cerebral palsy: confirmed as a specific type, including spastic hemiplegia, spastic diplegia, and ataxic type; 2. Age: children aged 6 to 17 years; 3. Cognitive ability: sufficient cognitive function to understand simple instructions, confirmed by a certified clinician; 4. Motor function: classified as levels I-III in the Gross Motor Function Classification System (GMFCS).

Exclusion criteria

Exclusion criteria: 1. Recent surgery or unresolved fractures: undergone surgery in the past year or have an unhealed fracture; 2. Neurological disorders: history of epilepsy, mental illness, or intellectual disabilities related to neurological health issues; 3. Other related conditions: acute thrombosis, tendonitis, kidney stones, disc disease, or arthritis that may affect physical conditions relevant to the study; 4. Fixed musculoskeletal deformities: acquired fixed deformities that may affect mobility; 5. Medication history: use of anabolic steroids, glucocorticoids (excluding inhaled forms), or growth hormones within the three months prior to enrollment; 6. Injection treatment history: received botulinum toxin injections in the lower limbs within the three months prior to enrollment; 7. Vascular diseases: acute thrombosis and lower limb venous thrombosis that may affect the safety of completing the study; 8. Implants or joint replacements: pacemakers, artificial joints (such as hip or knee), or other metal implants (such as screws or plates); 9. Severe osteoporosis and spinal disorders: patients with severe osteoporosis, herniated discs, or spinal instability; 10. Loss of sensation: loss of sensation in the upper and/or lower limbs.

Design outcomes

Primary

MeasureTime frame
The Gross Motor Function Measure 88 Score ;

Secondary

MeasureTime frame
Pediatric Balance Scale Score ;The Timed Up and Go (TUG) test;The 10-Meter Walk Test (10MWT);The Modified Ashworth Scale (MAS);Pediatric Quality of Life Inventory;

Countries

China

Contacts

Public ContactWang Ya Jie

Lanzhou Disabled Care Employment Rehabilitation Center

18168027832@163.com+86 931 4536357

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026